These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28944733)

  • 1. Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review.
    Yu JS; Chin L; Oh J; Farias J
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1028-1040. PubMed ID: 28944733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance-Based Risk-Sharing Arrangements: U.S. Payer Experience.
    Goble JA; Ung B; van Boemmel-Wegmann S; Navarro RP; Parece A
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1042-1052. PubMed ID: 28944728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic review.
    Chen Y; Carlson JJ
    J Manag Care Spec Pharm; 2022 Jan; 28(1):78-83. PubMed ID: 34949115
    [No Abstract]   [Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World?
    Kim AE; Choi DH; Chang J; Kim SH
    Clin Drug Investig; 2020 Dec; 40(12):1107-1113. PubMed ID: 33037566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Formulary Restrictions on Patient and Payer Outcomes: A Systematic Literature Review.
    Park Y; Raza S; George A; Agrawal R; Ko J
    J Manag Care Spec Pharm; 2017 Aug; 23(8):893-901. PubMed ID: 28737993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.
    J Manag Care Spec Pharm; 2017 Jan; 23(1):105-112. PubMed ID: 28025919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders.
    Nazareth T; Ko JJ; Sasane R; Frois C; Carpenter S; Demean S; Vegesna A; Wu E; Navarro RP
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1018-1026. PubMed ID: 28944734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory, Policy, and Operational Considerations for Outcomes-Based Risk-Sharing Agreements in the U.S. Market: Opportunities for Reform.
    Goodman C; Villarivera C; Gregor K; van Bavel J
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1174-1181. PubMed ID: 31535596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance-Based Risk-Sharing Arrangements: An Updated International Review.
    Carlson JJ; Chen S; Garrison LP
    Pharmacoeconomics; 2017 Oct; 35(10):1063-1072. PubMed ID: 28695544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of the Effect of Cancer Treatment on Work Productivity of Patients and Caregivers.
    Kamal KM; Covvey JR; Dashputre A; Ghosh S; Shah S; Bhosle M; Zacker C
    J Manag Care Spec Pharm; 2017 Feb; 23(2):136-162. PubMed ID: 28125370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.
    Gupta R; Dhruva SS; Fox ER; Ross JS
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1066-1076. PubMed ID: 28944731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.
    Frois C; Howe A; Jarvis J; Grice K; Wong K; Zacker C; Sasane R
    J Manag Care Spec Pharm; 2019 Feb; 25(2):246-259. PubMed ID: 30698093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International experience with performance-based risk-sharing arrangements: implications for the Chinese innovative pharmaceutical market.
    Xu W; Wu J
    Int J Technol Assess Health Care; 2020 Oct; 36(5):486-491. PubMed ID: 32962784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
    Pauly NJ; Talbert JC; Brown J
    J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMCP Partnership Forum: FDAMA Section 114-Improving the Exchange of Health Care Economic Data.
    J Manag Care Spec Pharm; 2016 Jul; 22(7):826-31. PubMed ID: 27333323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers.
    Carlson JJ; Gries KS; Yeung K; Sullivan SD; Garrison LP
    Appl Health Econ Health Policy; 2014 Jun; 12(3):231-8. PubMed ID: 24664994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.